UniProtKB - P00533 (EGFR_HUMAN)
(max 400 entries)x
Your basket is currently empty.
Select item(s) and click on "Add to basket" to create your own collection here
(400 entries max)
Protein
Epidermal growth factor receptor
Gene
EGFR
Organism
Homo sapiens (Human)
Status
Functioni
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity).By similarity
Isoform 2 may act as an antagonist of EGF action.
(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.1 Publication
Catalytic activityi
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.PROSITE-ProRule annotation6 Publications
Enzyme regulationi
Endocytosis and inhibition of the activated EGFR by phosphatases like PTPRJ and PTPRK constitute immediate regulatory mechanisms. Upon EGF-binding phosphorylates EPS15 that regulates EGFR endocytosis and activity. Moreover, inducible feedback inhibitors including LRIG1, SOCS4, SOCS5 and ERRFI1 constitute alternative regulatory mechanisms for the EGFR signaling.4 Publications
Sites
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Binding sitei | 745 | ATP | 1 | |
| Active sitei | 837 | Proton acceptorPROSITE-ProRule annotation | 1 | |
| Binding sitei | 855 | ATP | 1 | |
| Sitei | 1016 | Important for interaction with PIK3C2B | 1 |
Regions
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Nucleotide bindingi | 718 – 726 | ATP | 9 | |
| Nucleotide bindingi | 790 – 791 | ATP | 2 |
GO - Molecular functioni
- actin filament binding Source: UniProtKB
- ATP binding Source: UniProtKB-KW
- cadherin binding Source: BHF-UCL
- calmodulin binding Source: Ensembl
- chromatin binding Source: UniProtKB
- double-stranded DNA binding Source: UniProtKB
- enzyme binding Source: UniProtKB
- epidermal growth factor-activated receptor activity Source: UniProtKB
- epidermal growth factor binding Source: Ensembl
- glycoprotein binding Source: Ensembl
- identical protein binding Source: IntAct
- integrin binding Source: Ensembl
- MAP kinase kinase kinase activity Source: UniProtKB
- phosphatidylinositol-4,5-bisphosphate 3-kinase activity Source: Reactome
- protein heterodimerization activity Source: UniProtKB
- protein kinase binding Source: Ensembl
- protein phosphatase binding Source: UniProtKB
- protein tyrosine kinase activity Source: UniProtKB
- Ras guanyl-nucleotide exchange factor activity Source: Reactome
- signal transducer, downstream of receptor, with protein tyrosine kinase activity Source: InterPro
- transmembrane receptor protein tyrosine kinase activity Source: Reactome
- transmembrane signaling receptor activity Source: MGI
- ubiquitin protein ligase binding Source: UniProtKB
GO - Biological processi
- activation of phospholipase A2 activity by calcium-mediated signaling Source: UniProtKB
- activation of phospholipase C activity Source: UniProtKB
- astrocyte activation Source: Ensembl
- cell proliferation Source: UniProtKB
- cell surface receptor signaling pathway Source: MGI
- cellular response to amino acid stimulus Source: Ensembl
- cellular response to cadmium ion Source: CAFA
- cellular response to dexamethasone stimulus Source: Ensembl
- cellular response to drug Source: Ensembl
- cellular response to epidermal growth factor stimulus Source: UniProtKB
- cellular response to estradiol stimulus Source: UniProtKB
- cellular response to mechanical stimulus Source: Ensembl
- cellular response to reactive oxygen species Source: CAFA
- cerebral cortex cell migration Source: Ensembl
- circadian rhythm Source: Ensembl
- digestive tract morphogenesis Source: Ensembl
- diterpenoid metabolic process Source: Ensembl
- embryonic placenta development Source: Ensembl
- epidermal growth factor receptor signaling pathway Source: UniProtKB
- ERBB2 signaling pathway Source: Reactome
- eyelid development in camera-type eye Source: Ensembl
- hair follicle development Source: Ensembl
- hydrogen peroxide metabolic process Source: Ensembl
- learning or memory Source: UniProtKB
- liver regeneration Source: Ensembl
- lung development Source: Ensembl
- magnesium ion homeostasis Source: Ensembl
- MAPK cascade Source: Reactome
- membrane organization Source: Reactome
- midgut development Source: Ensembl
- morphogenesis of an epithelial fold Source: Ensembl
- negative regulation of apoptotic process Source: UniProtKB
- negative regulation of cardiocyte differentiation Source: BHF-UCL
- negative regulation of epidermal growth factor receptor signaling pathway Source: Reactome
- negative regulation of ERBB signaling pathway Source: Reactome
- negative regulation of mitotic cell cycle Source: Ensembl
- negative regulation of protein catabolic process Source: UniProtKB
- neuron projection morphogenesis Source: Ensembl
- ossification Source: UniProtKB
- ovulation cycle Source: Ensembl
- peptidyl-tyrosine autophosphorylation Source: ParkinsonsUK-UCL
- peptidyl-tyrosine phosphorylation Source: ParkinsonsUK-UCL
- phosphatidylinositol-mediated signaling Source: Reactome
- positive regulation of blood vessel diameter Source: Ensembl
- positive regulation of bone resorption Source: Ensembl
- positive regulation of catenin import into nucleus Source: BHF-UCL
- positive regulation of cell growth Source: UniProtKB
- positive regulation of cell migration Source: UniProtKB
- positive regulation of cell proliferation Source: MGI
- positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle Source: BHF-UCL
- positive regulation of DNA repair Source: UniProtKB
- positive regulation of DNA replication Source: UniProtKB
- positive regulation of epithelial cell proliferation Source: UniProtKB
- positive regulation of ERK1 and ERK2 cascade Source: UniProtKB
- positive regulation of fibroblast proliferation Source: Ensembl
- positive regulation of inflammatory response Source: Ensembl
- positive regulation of MAP kinase activity Source: UniProtKB
- positive regulation of NIK/NF-kappaB signaling Source: CAFA
- positive regulation of nitric oxide biosynthetic process Source: UniProtKB
- positive regulation of phosphorylation Source: UniProtKB
- positive regulation of production of miRNAs involved in gene silencing by miRNA Source: BHF-UCL
- positive regulation of prolactin secretion Source: Ensembl
- positive regulation of protein kinase B signaling Source: BHF-UCL
- positive regulation of protein kinase C activity Source: ParkinsonsUK-UCL
- positive regulation of protein localization to plasma membrane Source: ParkinsonsUK-UCL
- positive regulation of protein phosphorylation Source: UniProtKB
- positive regulation of smooth muscle cell proliferation Source: Ensembl
- positive regulation of superoxide anion generation Source: Ensembl
- positive regulation of synaptic transmission, glutamatergic Source: Ensembl
- positive regulation of transcription, DNA-templated Source: CAFA
- positive regulation of transcription from RNA polymerase II promoter Source: UniProtKB
- positive regulation of vasoconstriction Source: Ensembl
- protein autophosphorylation Source: UniProtKB
- protein insertion into membrane Source: UniProtKB
- regulation of cell motility Source: Reactome
- regulation of ERK1 and ERK2 cascade Source: CAFA
- regulation of JNK cascade Source: CAFA
- regulation of nitric-oxide synthase activity Source: UniProtKB
- regulation of peptidyl-tyrosine phosphorylation Source: UniProtKB
- regulation of phosphatidylinositol 3-kinase signaling Source: CAFA
- regulation of transcription from RNA polymerase II promoter Source: Reactome
- response to calcium ion Source: Ensembl
- response to cobalamin Source: Ensembl
- response to hydroxyisoflavone Source: Ensembl
- response to osmotic stress Source: Ensembl
- response to stress Source: UniProtKB
- response to UV-A Source: BHF-UCL
- salivary gland morphogenesis Source: Ensembl
- signal transduction Source: UniProtKB
- single organismal cell-cell adhesion Source: UniProtKB
- tongue development Source: Ensembl
- translation Source: Ensembl
- wound healing Source: Ensembl
Keywordsi
| Molecular function | Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase |
| Ligand | ATP-binding, Nucleotide-binding |
Enzyme and pathway databases
| BRENDAi | 2.7.10.1. 2681. |
| Reactomei | R-HSA-1227986. Signaling by ERBB2. R-HSA-1236382. Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. R-HSA-1236394. Signaling by ERBB4. R-HSA-1250196. SHC1 events in ERBB2 signaling. R-HSA-1251932. PLCG1 events in ERBB2 signaling. R-HSA-1257604. PIP3 activates AKT signaling. R-HSA-177929. Signaling by EGFR. R-HSA-179812. GRB2 events in EGFR signaling. R-HSA-180292. GAB1 signalosome. R-HSA-180336. SHC1 events in EGFR signaling. R-HSA-182971. EGFR downregulation. R-HSA-1963640. GRB2 events in ERBB2 signaling. R-HSA-1963642. PI3K events in ERBB2 signaling. R-HSA-212718. EGFR interacts with phospholipase C-gamma. R-HSA-2179392. EGFR Transactivation by Gastrin. R-HSA-2219530. Constitutive Signaling by Aberrant PI3K in Cancer. R-HSA-445144. Signal transduction by L1. R-HSA-5637810. Constitutive Signaling by EGFRvIII. R-HSA-5638303. Inhibition of Signaling by Overexpressed EGFR. R-HSA-5673001. RAF/MAP kinase cascade. R-HSA-6785631. ERBB2 Regulates Cell Motility. R-HSA-6811558. PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. R-HSA-8847993. ERBB2 Activates PTK6 Signaling. R-HSA-8856825. Cargo recognition for clathrin-mediated endocytosis. R-HSA-8856828. Clathrin-mediated endocytosis. R-HSA-8857538. PTK6 promotes HIF1A stabilization. R-HSA-8863795. Downregulation of ERBB2 signaling. R-HSA-8866910. TFAP2 (AP-2) family regulates transcription of growth factors and their receptors. |
| SignaLinki | P00533. |
| SIGNORi | P00533. |
Names & Taxonomyi
| Protein namesi | Recommended name: Epidermal growth factor receptor (EC:2.7.10.1)Alternative name(s): Proto-oncogene c-ErbB-1 Receptor tyrosine-protein kinase erbB-1 |
| Gene namesi | Name:EGFR Synonyms:ERBB, ERBB1, HER1 |
| Organismi | Homo sapiens (Human) |
| Taxonomic identifieri | 9606 [NCBI] |
| Taxonomic lineagei | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
| Proteomesi |
|
Organism-specific databases
| HGNCi | HGNC:3236. EGFR. |
Subcellular locationi
- Cell membrane; Single-pass type I membrane protein
- Endoplasmic reticulum membrane; Single-pass type I membrane protein
- Golgi apparatus membrane; Single-pass type I membrane protein
- Nucleus membrane; Single-pass type I membrane protein
- Endosome
- Endosome membrane
- Nucleus
Note: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER. Endocytosed upon activation by ligand. Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF).
Topology
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Topological domaini | 25 – 645 | ExtracellularSequence analysisAdd BLAST | 621 | |
| Transmembranei | 646 – 668 | HelicalSequence analysisAdd BLAST | 23 | |
| Topological domaini | 669 – 1210 | CytoplasmicSequence analysisAdd BLAST | 542 |
GO - Cellular componenti
- apical plasma membrane Source: Ensembl
- basolateral plasma membrane Source: BHF-UCL
- cell surface Source: UniProtKB
- clathrin-coated vesicle membrane Source: Reactome
- cytoplasm Source: UniProtKB
- early endosome membrane Source: UniProtKB
- endocytic vesicle Source: Ensembl
- endoplasmic reticulum membrane Source: UniProtKB-SubCell
- endosome Source: UniProtKB
- endosome membrane Source: UniProtKB
- extracellular space Source: UniProtKB
- focal adhesion Source: UniProtKB
- Golgi membrane Source: UniProtKB-SubCell
- integral component of membrane Source: UniProtKB-KW
- membrane Source: UniProtKB
- membrane raft Source: UniProtKB
- multivesicular body, internal vesicle lumen Source: UniProtKB
- nuclear membrane Source: UniProtKB-SubCell
- nucleus Source: UniProtKB
- perinuclear region of cytoplasm Source: Ensembl
- plasma membrane Source: HGNC
- receptor complex Source: MGI
- Shc-EGFR complex Source: BHF-UCL
- synapse Source: Ensembl
Keywords - Cellular componenti
Cell membrane, Endoplasmic reticulum, Endosome, Golgi apparatus, Membrane, Nucleus, SecretedPathology & Biotechi
Involvement in diseasei
Lung cancer (LNCR)3 Publications
The gene represented in this entry is involved in disease pathogenesis.
Disease descriptionA common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
See also OMIM:211980Inflammatory skin and bowel disease, neonatal, 2 (NISBD2)1 Publication
The disease is caused by mutations affecting the gene represented in this entry.
Disease descriptionA disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized.
See also OMIM:616069| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Natural variantiVAR_072435 | 428 | G → D in NISBD2; loss of function; the mutant does not localize to the cell membrane; has diffuse cytoplasmic localization. 1 PublicationCorresponds to variant dbSNP:rs606231253Ensembl. | 1 |
Mutagenesis
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Mutagenesisi | 275 | Y → A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309. 1 Publication | 1 | |
| Mutagenesisi | 287 | F → A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309. 1 Publication | 1 | |
| Mutagenesisi | 309 | R → S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287. 1 Publication | 1 | |
| Mutagenesisi | 429 | R → E: Abolishes autophosphorylation and activation of downstream kinases. 1 Publication | 1 | |
| Mutagenesisi | 587 – 590 | DGPH → AGPA: Decreases intramolecular interactions and facilitates EGF binding. 1 Publication | 4 | |
| Mutagenesisi | 609 | K → A: Decreases intramolecular interactions and facilitates EGF binding. 1 Publication | 1 | |
| Mutagenesisi | 688 | L → A: Strongly reduced phosphorylation. 2 Publications | 1 | |
| Mutagenesisi | 689 | V → A: Reduced autophosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 689 | V → M: Constitutively activated kinase. 1 Publication | 1 | |
| Mutagenesisi | 690 | E → A: Reduced phosphorylation. 2 Publications | 1 | |
| Mutagenesisi | 692 | L → A or P: Strongly reduced phosphorylation. 2 Publications | 1 | |
| Mutagenesisi | 693 | T → A: Increased phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 693 | T → D: Strongly reduced phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 694 | P → A: Strongly reduced phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 699 | P → A: Reduced phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 700 | N → A: Abolishes phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 704 | L → A: Abolishes phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 705 | R → A: Abolishes phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 706 | I → A: Abolishes phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 745 | K → A or M: Abolishes kinase activity. 1 Publication | 1 | |
| Mutagenesisi | 974 | D → A: Strongly reduced phosphorylation. | 1 | |
| Mutagenesisi | 977 | R → A: Reduced phosphorylation. 1 Publication | 1 | |
| Mutagenesisi | 1005 – 1006 | ED → RK: Constitutively activated kinase. 1 Publication | 2 | |
| Mutagenesisi | 1016 | Y → F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092. 1 Publication | 1 | |
| Mutagenesisi | 1067 | Q → G: No effect on interaction with CBLC. 1 Publication | 1 | |
| Mutagenesisi | 1068 | R → G: Strongly decreases interaction with CBLC. 1 Publication | 1 | |
| Mutagenesisi | 1069 | Y → F: Abolishes interaction with CBLC. 1 Publication | 1 | |
| Mutagenesisi | 1092 | Y → F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016. 1 Publication | 1 | |
| Mutagenesisi | 1110 | Y → F: No change in interaction with PIK3C2B. 1 Publication | 1 | |
| Mutagenesisi | 1172 | Y → F: No change in interaction with PIK3C2B. 1 Publication | 1 | |
| Mutagenesisi | 1197 | Y → F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016. 1 Publication | 1 |
Keywords - Diseasei
Disease mutation, Proto-oncogeneOrganism-specific databases
| DisGeNETi | 1956. |
| MalaCardsi | EGFR. |
| MIMi | 211980. phenotype. 616069. phenotype. |
| OpenTargetsi | ENSG00000146648. |
| Orphaneti | 251579. Giant cell glioblastoma. 251576. Gliosarcoma. 294023. Neonatal inflammatory skin and bowel disease. 357191. Selection of therapeutic option in non-small cell lung carcinoma. |
| PharmGKBi | PA7360. |
Chemistry databases
| ChEMBLi | CHEMBL203. |
| DrugBanki | DB08916. Afatinib. DB00002. Cetuximab. DB05424. CI-1033. DB00530. Erlotinib. DB03496. Flavopiridol. DB00317. Gefitinib. DB05324. HuMax-EGFr. DB11737. Icotinib. DB04988. IGN311. DB05774. IMC-11F8. DB05900. INSM-18. DB01259. Lapatinib. DB00281. Lidocaine. DB05101. Matuzumab. DB07662. N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE. DB09559. Necitumumab. DB13164. Olmutinib. DB09330. Osimertinib. DB01269. Panitumumab. DB05374. Rindopepimut. DB07602. S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE. DB00072. Trastuzumab. DB05294. Vandetanib. |
| GuidetoPHARMACOLOGYi | 1797. |
Polymorphism and mutation databases
| BioMutai | EGFR. |
| DMDMi | 2811086. |
PTM / Processingi
Molecule processing
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Signal peptidei | 1 – 24 | 2 PublicationsAdd BLAST | 24 | |
| ChainiPRO_0000016665 | 25 – 1210 | Epidermal growth factor receptorAdd BLAST | 1186 |
Amino acid modifications
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Disulfide bondi | 31 ↔ 58 | |||
| GlycosylationiCAR_000227 | 56 | N-linked (GlcNAc...) (complex) asparagine; atypical; partial5 Publications | 1 | |
| Glycosylationi | 73 | N-linked (GlcNAc...) asparagine; atypical1 Publication | 1 | |
| Glycosylationi | 128 | N-linked (GlcNAc...) asparagine3 Publications | 1 | |
| Disulfide bondi | 157 ↔ 187 | |||
| Glycosylationi | 175 | N-linked (GlcNAc...) asparagine5 Publications | 1 | |
| Disulfide bondi | 190 ↔ 199 | |||
| Disulfide bondi | 194 ↔ 207 | |||
| Glycosylationi | 196 | N-linked (GlcNAc...) asparagine4 Publications | 1 | |
| Disulfide bondi | 215 ↔ 223 | |||
| Disulfide bondi | 219 ↔ 231 | |||
| Modified residuei | 229 | Phosphoserine1 Publication | 1 | |
| Disulfide bondi | 232 ↔ 240 | |||
| Disulfide bondi | 236 ↔ 248 | |||
| Disulfide bondi | 251 ↔ 260 | |||
| Disulfide bondi | 264 ↔ 291 | |||
| Disulfide bondi | 295 ↔ 307 | |||
| Disulfide bondi | 311 ↔ 326 | |||
| Disulfide bondi | 329 ↔ 333 | |||
| Disulfide bondi | 337 ↔ 362 | |||
| Glycosylationi | 352 | N-linked (GlcNAc...) asparagine7 Publications | 1 | |
| Glycosylationi | 361 | N-linked (GlcNAc...) asparagine6 Publications | 1 | |
| Glycosylationi | 413 | N-linked (GlcNAc...) asparagine4 Publications | 1 | |
| Glycosylationi | 444 | N-linked (GlcNAc...) asparagine6 Publications | 1 | |
| Disulfide bondi | 470 ↔ 499 | |||
| Disulfide bondi | 506 ↔ 515 | |||
| Disulfide bondi | 510 ↔ 523 | |||
| Disulfide bondi | 526 ↔ 535 | |||
| Glycosylationi | 528 | N-linked (GlcNAc...) asparagine5 Publications | 1 | |
| Disulfide bondi | 539 ↔ 555 | |||
| Disulfide bondi | 558 ↔ 571 | |||
| Disulfide bondi | 562 ↔ 579 | |||
| Glycosylationi | 568 | N-linked (GlcNAc...) asparagine; partial5 Publications | 1 | |
| Disulfide bondi | 582 ↔ 591 | |||
| Disulfide bondi | 595 ↔ 617 | |||
| Glycosylationi | 603 | N-linked (GlcNAc...) asparagine; partial4 Publications | 1 | |
| Disulfide bondi | 620 ↔ 628 | |||
| Glycosylationi | 623 | N-linked (GlcNAc...) (high mannose) asparagine1 Publication | 1 | |
| Disulfide bondi | 624 ↔ 636 | |||
| Modified residuei | 678 | Phosphothreonine; by PKC and PKD/PRKD11 Publication | 1 | |
| Modified residuei | 693 | Phosphothreonine; by PKD/PRKD1Combined sources3 Publications | 1 | |
| Modified residuei | 695 | PhosphoserineCombined sources1 Publication | 1 | |
| Cross-linki | 716 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication | ||
| Cross-linki | 737 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication | ||
| Cross-linki | 754 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication | ||
| Cross-linki | 867 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication | ||
| Cross-linki | 929 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication | ||
| Cross-linki | 970 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)1 Publication | ||
| Modified residuei | 991 | PhosphoserineCombined sources1 Publication | 1 | |
| Modified residuei | 995 | PhosphoserineCombined sources | 1 | |
| Modified residuei | 998 | Phosphotyrosine; by autocatalysisCombined sources1 Publication | 1 | |
| Modified residuei | 1016 | Phosphotyrosine; by autocatalysis1 Publication | 1 | |
| Modified residuei | 1026 | PhosphoserineCombined sources1 Publication | 1 | |
| Modified residuei | 1039 | PhosphoserineCombined sources | 1 | |
| Modified residuei | 1041 | PhosphothreonineCombined sources | 1 | |
| Modified residuei | 1042 | PhosphoserineCombined sources | 1 | |
| Modified residuei | 1064 | PhosphoserineCombined sources | 1 | |
| Modified residuei | 1069 | Phosphotyrosine1 Publication | 1 | |
| Modified residuei | 1070 | Phosphoserine1 Publication | 1 | |
| Modified residuei | 1071 | Phosphoserine1 Publication | 1 | |
| Modified residuei | 1081 | PhosphoserineCombined sources | 1 | |
| Modified residuei | 1092 | Phosphotyrosine; by autocatalysis1 Publication | 1 | |
| Modified residuei | 1110 | Phosphotyrosine; by autocatalysis2 Publications | 1 | |
| Modified residuei | 1166 | PhosphoserineCombined sources | 1 | |
| Modified residuei | 1172 | Phosphotyrosine; by autocatalysisCombined sources | 1 | |
| Modified residuei | 1197 | Phosphotyrosine; by autocatalysisCombined sources2 Publications | 1 | |
| Modified residuei | 1199 | Omega-N-methylarginine1 Publication | 1 |
Post-translational modificationi
Phosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3. Dephosphorylated by PTPN1 and PTPN2.8 Publications
Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B prevents degradation. Ubiquitinated by RNF115 and RNF126 (By similarity).By similarity3 Publications
Methylated. Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197.3 Publications
Keywords - PTMi
Disulfide bond, Glycoprotein, Isopeptide bond, Methylation, Phosphoprotein, Ubl conjugationProteomic databases
| EPDi | P00533. |
| MaxQBi | P00533. |
| PaxDbi | P00533. |
| PeptideAtlasi | P00533. |
| PRIDEi | P00533. |
2D gel databases
| SWISS-2DPAGEi | P00533. |
PTM databases
| iPTMneti | P00533. |
| PhosphoSitePlusi | P00533. |
| SwissPalmi | P00533. |
| UniCarbKBi | P00533. |
Miscellaneous databases
| PMAP-CutDBi | P00533. |
Expressioni
Tissue specificityi
Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.1 Publication
Gene expression databases
| Bgeei | ENSG00000146648. |
| ExpressionAtlasi | P00533. baseline and differential. |
| Genevisiblei | P00533. HS. |
Organism-specific databases
| HPAi | CAB000035. CAB068186. CAB073534. HPA001200. HPA018530. |
Interactioni
Subunit structurei
Binding of the ligand triggers homo- and/or heterodimerization of the receptor triggering its autophosphorylation. Heterodimer with ERBB2. Interacts with ERRFI1; inhibits dimerization of the kinase domain and autophosphorylation. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. Interacts with GRB2; an adapter protein coupling the receptor to downstream signaling pathways. Interacts with GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; mediates EGFR downstream signaling in cell proliferation. Interacts with RIPK1; involved in NF-kappa-B activation. Interacts (autophosphorylated) with CBL, CBLB and CBLC; involved in EGFR ubiquitination and regulation. Interacts with SOCS5; regulates EGFR degradation through ELOC- and ELOB-mediated ubiquitination and proteasomal degradation. Interacts with PRMT5; methylates EGFR and enhances interaction with PTPN6. Interacts (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of MAPK/ERK. Interacts with COPG1; essential for regulation of EGF-dependent nuclear transport of EGFR by retrograde trafficking from the Golgi to the ER. Interacts with TNK2; this interaction is dependent on EGF stimulation and kinase activity of EGFR. Interacts with PCNA; positively regulates PCNA. Interacts with PELP1. Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 domains) with GRB2, NCK1 and NCK2. Interacts with ATX2. Interacts with GAREM1. Interacts (ubiquitinated) with ANKRD13A/B/D; the interaction is direct and may regulate EGFR internalization after EGF stimulation. Interacts with GPER1; the interaction occurs in an estrogen-dependent manner. Interacts (via C-terminal cytoplasmic kinase domain) with ZPR1 (via zinc fingers). Interacts with RNF115 and RNF126. Interacts with GPRC5A (via its transmembrane domain)(PubMed:25311788). Interacts with FAM83B; positively regulates EGFR inducing its autophospharylation in absence of stimulation by EGF (PubMed:23912460).38 Publications
Binary interactionsi
GO - Molecular functioni
- actin filament binding Source: UniProtKB
- cadherin binding Source: BHF-UCL
- calmodulin binding Source: Ensembl
- enzyme binding Source: UniProtKB
- epidermal growth factor binding Source: Ensembl
- glycoprotein binding Source: Ensembl
- identical protein binding Source: IntAct
- integrin binding Source: Ensembl
- protein heterodimerization activity Source: UniProtKB
- protein kinase binding Source: Ensembl
- protein phosphatase binding Source: UniProtKB
- ubiquitin protein ligase binding Source: UniProtKB
Protein-protein interaction databases
| BioGridi | 108276. 886 interactors. |
| DIPi | DIP-405N. |
| IntActi | P00533. 479 interactors. |
| MINTi | MINT-206389. |
| STRINGi | 9606.ENSP00000275493. |
Chemistry databases
| BindingDBi | P00533. |
Structurei
Secondary structure
Legend: HelixTurnBeta strandPDB Structure known for this area
Show more details| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Beta strandi | 40 – 43 | Combined sources | 4 | |
| Helixi | 44 – 55 | Combined sources | 12 | |
| Beta strandi | 60 – 69 | Combined sources | 10 | |
| Helixi | 77 – 81 | Combined sources | 5 | |
| Beta strandi | 84 – 87 | Combined sources | 4 | |
| Beta strandi | 89 – 93 | Combined sources | 5 | |
| Helixi | 101 – 103 | Combined sources | 3 | |
| Turni | 114 – 116 | Combined sources | 3 | |
| Beta strandi | 117 – 122 | Combined sources | 6 | |
| Beta strandi | 125 – 129 | Combined sources | 5 | |
| Beta strandi | 145 – 152 | Combined sources | 8 | |
| Helixi | 159 – 161 | Combined sources | 3 | |
| Helixi | 164 – 166 | Combined sources | 3 | |
| Helixi | 170 – 173 | Combined sources | 4 | |
| Helixi | 195 – 197 | Combined sources | 3 | |
| Beta strandi | 199 – 204 | Combined sources | 6 | |
| Beta strandi | 211 – 214 | Combined sources | 4 | |
| Beta strandi | 223 – 227 | Combined sources | 5 | |
| Helixi | 228 – 230 | Combined sources | 3 | |
| Beta strandi | 236 – 238 | Combined sources | 3 | |
| Beta strandi | 240 – 244 | Combined sources | 5 | |
| Turni | 245 – 247 | Combined sources | 3 | |
| Beta strandi | 248 – 256 | Combined sources | 9 | |
| Beta strandi | 259 – 263 | Combined sources | 5 | |
| Beta strandi | 267 – 271 | Combined sources | 5 | |
| Turni | 272 – 275 | Combined sources | 4 | |
| Beta strandi | 276 – 279 | Combined sources | 4 | |
| Beta strandi | 285 – 287 | Combined sources | 3 | |
| Beta strandi | 290 – 294 | Combined sources | 5 | |
| Turni | 296 – 298 | Combined sources | 3 | |
| Beta strandi | 299 – 301 | Combined sources | 3 | |
| Beta strandi | 303 – 305 | Combined sources | 3 | |
| Beta strandi | 306 – 310 | Combined sources | 5 | |
| Beta strandi | 313 – 315 | Combined sources | 3 | |
| Beta strandi | 318 – 320 | Combined sources | 3 | |
| Beta strandi | 323 – 325 | Combined sources | 3 | |
| Beta strandi | 330 – 332 | Combined sources | 3 | |
| Beta strandi | 336 – 338 | Combined sources | 3 | |
| Turni | 340 – 342 | Combined sources | 3 | |
| Helixi | 343 – 345 | Combined sources | 3 | |
| Beta strandi | 349 – 351 | Combined sources | 3 | |
| Turni | 353 – 355 | Combined sources | 3 | |
| Helixi | 356 – 359 | Combined sources | 4 | |
| Beta strandi | 363 – 367 | Combined sources | 5 | |
| Beta strandi | 369 – 371 | Combined sources | 3 | |
| Helixi | 373 – 377 | Combined sources | 5 | |
| Turni | 380 – 383 | Combined sources | 4 | |
| Helixi | 389 – 397 | Combined sources | 9 | |
| Beta strandi | 400 – 403 | Combined sources | 4 | |
| Beta strandi | 405 – 407 | Combined sources | 3 | |
| Helixi | 418 – 420 | Combined sources | 3 | |
| Turni | 433 – 435 | Combined sources | 3 | |
| Beta strandi | 436 – 442 | Combined sources | 7 | |
| Beta strandi | 458 – 464 | Combined sources | 7 | |
| Helixi | 472 – 474 | Combined sources | 3 | |
| Helixi | 477 – 480 | Combined sources | 4 | |
| Beta strandi | 481 – 483 | Combined sources | 3 | |
| Beta strandi | 488 – 494 | Combined sources | 7 | |
| Helixi | 496 – 501 | Combined sources | 6 | |
| Beta strandi | 508 – 510 | Combined sources | 3 | |
| Beta strandi | 515 – 519 | Combined sources | 5 | |
| Helixi | 520 – 522 | Combined sources | 3 | |
| Beta strandi | 523 – 526 | Combined sources | 4 | |
| Beta strandi | 531 – 533 | Combined sources | 3 | |
| Beta strandi | 535 – 537 | Combined sources | 3 | |
| Beta strandi | 540 – 546 | Combined sources | 7 | |
| Beta strandi | 548 – 551 | Combined sources | 4 | |
| Beta strandi | 554 – 557 | Combined sources | 4 | |
| Beta strandi | 560 – 562 | Combined sources | 3 | |
| Beta strandi | 566 – 568 | Combined sources | 3 | |
| Beta strandi | 570 – 575 | Combined sources | 6 | |
| Beta strandi | 578 – 587 | Combined sources | 10 | |
| Beta strandi | 590 – 594 | Combined sources | 5 | |
| Beta strandi | 597 – 602 | Combined sources | 6 | |
| Beta strandi | 606 – 611 | Combined sources | 6 | |
| Beta strandi | 615 – 619 | Combined sources | 5 | |
| Beta strandi | 629 – 632 | Combined sources | 4 | |
| Helixi | 633 – 635 | Combined sources | 3 | |
| Beta strandi | 643 – 646 | Combined sources | 4 | |
| Helixi | 648 – 669 | Combined sources | 22 | |
| Beta strandi | 671 – 673 | Combined sources | 3 | |
| Helixi | 679 – 684 | Combined sources | 6 | |
| Helixi | 685 – 687 | Combined sources | 3 | |
| Beta strandi | 688 – 692 | Combined sources | 5 | |
| Beta strandi | 694 – 697 | Combined sources | 4 | |
| Beta strandi | 703 – 706 | Combined sources | 4 | |
| Helixi | 709 – 711 | Combined sources | 3 | |
| Beta strandi | 712 – 721 | Combined sources | 10 | |
| Beta strandi | 724 – 731 | Combined sources | 8 | |
| Turni | 734 – 736 | Combined sources | 3 | |
| Beta strandi | 740 – 747 | Combined sources | 8 | |
| Beta strandi | 748 – 750 | Combined sources | 3 | |
| Turni | 753 – 755 | Combined sources | 3 | |
| Helixi | 756 – 767 | Combined sources | 12 | |
| Beta strandi | 772 – 774 | Combined sources | 3 | |
| Beta strandi | 777 – 791 | Combined sources | 15 | |
| Beta strandi | 794 – 797 | Combined sources | 4 | |
| Helixi | 798 – 804 | Combined sources | 7 | |
| Helixi | 806 – 808 | Combined sources | 3 | |
| Helixi | 811 – 830 | Combined sources | 20 | |
| Helixi | 840 – 842 | Combined sources | 3 | |
| Beta strandi | 843 – 847 | Combined sources | 5 | |
| Beta strandi | 850 – 853 | Combined sources | 4 | |
| Helixi | 858 – 862 | Combined sources | 5 | |
| Turni | 863 – 865 | Combined sources | 3 | |
| Beta strandi | 867 – 870 | Combined sources | 4 | |
| Beta strandi | 873 – 876 | Combined sources | 4 | |
| Helixi | 878 – 880 | Combined sources | 3 | |
| Helixi | 883 – 888 | Combined sources | 6 | |
| Helixi | 893 – 908 | Combined sources | 16 | |
| Turni | 909 – 911 | Combined sources | 3 | |
| Turni | 914 – 917 | Combined sources | 4 | |
| Helixi | 920 – 922 | Combined sources | 3 | |
| Helixi | 923 – 928 | Combined sources | 6 | |
| Beta strandi | 937 – 939 | Combined sources | 3 | |
| Helixi | 941 – 950 | Combined sources | 10 | |
| Beta strandi | 951 – 953 | Combined sources | 3 | |
| Helixi | 955 – 957 | Combined sources | 3 | |
| Helixi | 961 – 972 | Combined sources | 12 | |
| Helixi | 975 – 977 | Combined sources | 3 | |
| Helixi | 984 – 986 | Combined sources | 3 | |
| Turni | 992 – 998 | Combined sources | 7 | |
| Beta strandi | 1004 – 1010 | Combined sources | 7 | |
| Helixi | 1013 – 1016 | Combined sources | 4 | |
| Beta strandi | 1068 – 1070 | Combined sources | 3 |
3D structure databases
| Select the link destinations: PDBei RCSB PDBi PDBji Links Updated | PDB entry | Method | Resolution (Å) | Chain | Positions | PDBsum |
| 1DNQ | model | - | A | 25-336 | [»] | |
| 1DNR | model | - | A | 337-645 | [»] | |
| 1IVO | X-ray | 3.30 | A/B | 25-646 | [»] | |
| 1M14 | X-ray | 2.60 | A | 695-1022 | [»] | |
| 1M17 | X-ray | 2.60 | A | 695-1022 | [»] | |
| 1MOX | X-ray | 2.50 | A/B | 25-525 | [»] | |
| 1NQL | X-ray | 2.80 | A | 25-642 | [»] | |
| 1XKK | X-ray | 2.40 | A | 695-1022 | [»] | |
| 1YY9 | X-ray | 2.60 | A | 25-642 | [»] | |
| 1Z9I | NMR | - | A | 669-721 | [»] | |
| 2EB2 | X-ray | 2.50 | A | 695-1022 | [»] | |
| 2EB3 | X-ray | 2.84 | A | 695-1022 | [»] | |
| 2EXP | model | - | A | 311-326 | [»] | |
| 2EXQ | model | - | A | 27-536 | [»] | |
| 2GS2 | X-ray | 2.80 | A | 696-1022 | [»] | |
| 2GS6 | X-ray | 2.60 | A | 696-1022 | [»] | |
| 2GS7 | X-ray | 2.60 | A/B | 696-1022 | [»] | |
| 2ITN | X-ray | 2.47 | A | 696-1019 | [»] | |
| 2ITO | X-ray | 3.25 | A | 696-1022 | [»] | |
| 2ITP | X-ray | 2.74 | A | 696-1022 | [»] | |
| 2ITQ | X-ray | 2.68 | A | 696-1022 | [»] | |
| 2ITT | X-ray | 2.73 | A | 696-1022 | [»] | |
| 2ITU | X-ray | 2.80 | A | 696-1022 | [»] | |
| 2ITV | X-ray | 2.47 | A | 696-1022 | [»] | |
| 2ITW | X-ray | 2.88 | A | 696-1022 | [»] | |
| 2ITX | X-ray | 2.98 | A | 696-1022 | [»] | |
| 2ITY | X-ray | 3.42 | A | 696-1022 | [»] | |
| 2ITZ | X-ray | 2.72 | A | 696-1022 | [»] | |
| 2J5E | X-ray | 3.10 | A | 696-1022 | [»] | |
| 2J5F | X-ray | 3.00 | A | 696-1022 | [»] | |
| 2J6M | X-ray | 3.10 | A | 696-1022 | [»] | |
| 2JIT | X-ray | 3.10 | A/B | 696-1022 | [»] | |
| 2JIU | X-ray | 3.05 | A/B | 695-1022 | [»] | |
| 2JIV | X-ray | 3.50 | A/B | 695-1022 | [»] | |
| 2KS1 | NMR | - | B | 634-677 | [»] | |
| 2M0B | NMR | - | A/B | 634-677 | [»] | |
| 2M20 | NMR | - | A/B | 642-697 | [»] | |
| 2N5S | NMR | - | A | 642-690 | [»] | |
| 2RF9 | X-ray | 3.50 | A/B | 696-1022 | [»] | |
| 2RFD | X-ray | 3.60 | A/B | 702-1022 | [»] | |
| 2RFE | X-ray | 2.90 | A/B/C/D | 702-1022 | [»] | |
| 2RGP | X-ray | 2.00 | A | 702-1016 | [»] | |
| 3B2U | X-ray | 2.58 | A/B/E/I/M/P/S/V | 335-538 | [»] | |
| 3B2V | X-ray | 3.30 | A | 25-642 | [»] | |
| 3BEL | X-ray | 2.30 | A | 702-1016 | [»] | |
| 3BUO | X-ray | 2.60 | A/C | 1063-1075 | [»] | |
| 3C09 | X-ray | 3.20 | A/D | 336-538 | [»] | |
| 3G5V | X-ray | 2.00 | C | 311-326 | [»] | |
| 3G5Y | X-ray | 1.59 | E | 311-326 | [»] | |
| 3GOP | X-ray | 2.80 | A | 669-1022 | [»] | |
| 3GT8 | X-ray | 2.96 | A/B/C/D | 696-1022 | [»] | |
| 3IKA | X-ray | 2.90 | A/B | 694-1022 | [»] | |
| 3LZB | X-ray | 2.70 | A/B/C/D/E/F/G/H | 696-983 | [»] | |
| 3NJP | X-ray | 3.30 | A/B | 25-638 | [»] | |
| 3OB2 | X-ray | 2.10 | A | 1063-1074 | [»] | |
| 3OP0 | X-ray | 2.52 | C/D | 1066-1076 | [»] | |
| 3P0Y | X-ray | 1.80 | A | 334-538 | [»] | |
| 3PFV | X-ray | 2.27 | C/D | 1066-1076 | [»] | |
| 3POZ | X-ray | 1.50 | A | 696-1022 | [»] | |
| 3QWQ | X-ray | 2.75 | A | 1-642 | [»] | |
| 3UG1 | X-ray | 2.75 | A | 695-1022 | [»] | |
| 3UG2 | X-ray | 2.50 | A | 695-1022 | [»] | |
| 3VJN | X-ray | 2.34 | A | 695-1022 | [»] | |
| 3VJO | X-ray | 2.64 | A | 695-1022 | [»] | |
| 3VRP | X-ray | 1.52 | B | 1062-1074 | [»] | |
| 3VRR | X-ray | 2.00 | C | 1062-1074 | [»] | |
| 3W2O | X-ray | 2.35 | A | 698-1022 | [»] | |
| 3W2P | X-ray | 2.05 | A | 698-1022 | [»] | |
| 3W2Q | X-ray | 2.20 | A | 698-1022 | [»] | |
| 3W2R | X-ray | 2.05 | A | 698-1022 | [»] | |
| 3W2S | X-ray | 1.90 | A | 696-1022 | [»] | |
| 3W32 | X-ray | 1.80 | A | 696-1022 | [»] | |
| 3W33 | X-ray | 1.70 | A | 696-1022 | [»] | |
| 4G5J | X-ray | 2.80 | A | 696-1022 | [»] | |
| 4G5P | X-ray | 3.17 | A/B | 696-1022 | [»] | |
| 4HJO | X-ray | 2.75 | A | 696-1022 | [»] | |
| 4I1Z | X-ray | 3.00 | A | 695-1022 | [»] | |
| 4I20 | X-ray | 3.34 | A | 695-1022 | [»] | |
| 4I21 | X-ray | 3.37 | A/B | 695-1022 | [»] | |
| 4I22 | X-ray | 1.71 | A | 695-1022 | [»] | |
| 4I23 | X-ray | 2.80 | A | 695-1022 | [»] | |
| 4I24 | X-ray | 1.80 | A/B | 695-1022 | [»] | |
| 4JQ7 | X-ray | 2.73 | A | 696-1021 | [»] | |
| 4JQ8 | X-ray | 2.83 | A | 696-1021 | [»] | |
| 4JR3 | X-ray | 2.70 | A | 696-1021 | [»] | |
| 4JRV | X-ray | 2.80 | A | 696-1021 | [»] | |
| 4KRL | X-ray | 2.85 | A | 335-538 | [»] | |
| 4KRM | X-ray | 2.66 | A/C/E/G/I/K | 335-538 | [»] | |
| 4KRO | X-ray | 3.05 | A | 25-642 | [»] | |
| 4KRP | X-ray | 2.82 | A | 25-642 | [»] | |
| 4LI5 | X-ray | 2.64 | A | 696-1020 | [»] | |
| 4LL0 | X-ray | 4.00 | A/B | 694-1022 | [»] | |
| 4LQM | X-ray | 2.50 | A | 694-1022 | [»] | |
| 4LRM | X-ray | 3.53 | A/B/C/D/E | 694-1022 | [»] | |
| 4R3P | X-ray | 2.90 | A | 696-1018 | [»] | |
| 4R3R | X-ray | 3.25 | A | 696-1018 | [»] | |
| 4R5S | X-ray | 3.00 | A | 696-1022 | [»] | |
| 4RIW | X-ray | 3.10 | B/D | 682-1022 | [»] | |
| 4RIX | X-ray | 3.10 | B/D | 682-1022 | [»] | |
| 4RIY | X-ray | 2.98 | B/D | 682-1022 | [»] | |
| 4RJ4 | X-ray | 2.78 | A | 695-1022 | [»] | |
| 4RJ5 | X-ray | 3.10 | A | 695-1022 | [»] | |
| 4RJ6 | X-ray | 2.70 | A | 695-1022 | [»] | |
| 4RJ7 | X-ray | 2.55 | A | 695-1022 | [»] | |
| 4RJ8 | X-ray | 2.50 | A | 695-1022 | [»] | |
| 4TKS | X-ray | 3.20 | A | 695-1022 | [»] | |
| 4UIP | X-ray | 2.95 | A | 26-637 | [»] | |
| 4UV7 | X-ray | 2.10 | A | 25-645 | [»] | |
| 4WD5 | X-ray | 3.30 | A/B | 694-1022 | [»] | |
| 4WKQ | X-ray | 1.85 | A | 696-1022 | [»] | |
| 4WRG | X-ray | 1.90 | A | 696-1022 | [»] | |
| 4ZAU | X-ray | 2.80 | A | 696-1022 | [»] | |
| 4ZJV | X-ray | 2.70 | A/B | 695-1022 | [»] | |
| 4ZSE | X-ray | 1.97 | A/B/C/D | 695-1022 | [»] | |
| 5C8K | X-ray | 3.00 | A | 695-1022 | [»] | |
| 5C8M | X-ray | 2.90 | A | 695-1022 | [»] | |
| 5C8N | X-ray | 2.40 | A | 695-1022 | [»] | |
| 5CAL | X-ray | 2.70 | A | 695-1022 | [»] | |
| 5CAN | X-ray | 2.80 | A | 695-1022 | [»] | |
| 5CAO | X-ray | 2.60 | A | 695-1022 | [»] | |
| 5CAP | X-ray | 2.40 | A | 695-1022 | [»] | |
| 5CAQ | X-ray | 2.50 | A | 695-1022 | [»] | |
| 5CAS | X-ray | 2.10 | A | 695-1022 | [»] | |
| 5CAU | X-ray | 2.25 | A | 695-1022 | [»] | |
| 5CAV | X-ray | 2.73 | A | 695-1022 | [»] | |
| 5CNN | X-ray | 1.90 | A/B | 696-1042 | [»] | |
| 5CNO | X-ray | 1.55 | A/B/X | 696-1022 | [»] | |
| 5CZH | X-ray | 2.80 | A | 694-1022 | [»] | |
| 5CZI | X-ray | 2.60 | A | 694-1022 | [»] | |
| 5D41 | X-ray | 2.31 | A/B | 695-1022 | [»] | |
| 5EDP | X-ray | 2.90 | A | 695-1022 | [»] | |
| 5EDQ | X-ray | 2.80 | A | 695-1022 | [»] | |
| 5EDR | X-ray | 2.60 | A | 695-1022 | [»] | |
| 5EM5 | X-ray | 2.65 | A | 695-1022 | [»] | |
| 5EM6 | X-ray | 2.78 | A | 695-1022 | [»] | |
| 5EM7 | X-ray | 2.81 | A | 695-1022 | [»] | |
| 5EM8 | X-ray | 2.80 | A | 695-1022 | [»] | |
| 5FED | X-ray | 2.65 | A | 696-1022 | [»] | |
| 5FEE | X-ray | 2.70 | A | 696-1022 | [»] | |
| 5FEQ | X-ray | 3.40 | A | 696-1022 | [»] | |
| 5GNK | X-ray | 1.80 | A | 696-988 | [»] | |
| 5HCX | X-ray | 2.60 | A | 696-1022 | [»] | |
| 5HCY | X-ray | 2.46 | A | 696-1022 | [»] | |
| 5HCZ | X-ray | 2.62 | A | 696-1022 | [»] | |
| 5HG5 | X-ray | 1.52 | A | 695-1022 | [»] | |
| 5HG7 | X-ray | 1.85 | A | 695-1022 | [»] | |
| 5HG8 | X-ray | 1.42 | A | 695-1022 | [»] | |
| 5HG9 | X-ray | 2.15 | A | 695-1022 | [»] | |
| 5HIB | X-ray | 2.85 | A | 695-1022 | [»] | |
| 5HIC | X-ray | 2.60 | A | 695-1022 | [»] | |
| 5J9Y | X-ray | 2.80 | A | 697-1019 | [»] | |
| 5J9Z | X-ray | 2.50 | A | 696-1020 | [»] | |
| 5JEB | X-ray | 3.30 | A | 696-1022 | [»] | |
| 5LV6 | NMR | - | A/B | 634-677 | [»] | |
| 5SX4 | X-ray | 2.80 | M/N | 335-525 | [»] | |
| 5SX5 | X-ray | 2.50 | M/N | 335-525 | [»] | |
| 5U8L | X-ray | 1.60 | A | 695-1022 | [»] | |
| 5UG8 | X-ray | 1.46 | A | 695-1022 | [»] | |
| 5UG9 | X-ray | 1.33 | A | 695-1022 | [»] | |
| 5UGA | X-ray | 1.82 | A | 695-1022 | [»] | |
| 5UGB | X-ray | 2.53 | A | 695-1022 | [»] | |
| 5UGC | X-ray | 1.58 | A | 695-1022 | [»] | |
| DisProti | DP00309. | |||||
| ProteinModelPortali | P00533. | |||||
| SMRi | P00533. | |||||
| ModBasei | Search... | |||||
| MobiDBi | Search... | |||||
Miscellaneous databases
| EvolutionaryTracei | P00533. |
Family & Domainsi
Domains and Repeats
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Repeati | 75 – 300 | ApproximateAdd BLAST | 226 | |
| Repeati | 390 – 600 | ApproximateAdd BLAST | 211 | |
| Domaini | 712 – 979 | Protein kinasePROSITE-ProRule annotationAdd BLAST | 268 |
Region
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Regioni | 688 – 704 | Important for dimerization, phosphorylation and activationAdd BLAST | 17 |
Sequence similaritiesi
Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.PROSITE-ProRule annotation
Keywords - Domaini
Repeat, Signal, Transmembrane, Transmembrane helixPhylogenomic databases
| eggNOGi | KOG1025. Eukaryota. ENOG410XNSR. LUCA. |
| GeneTreei | ENSGT00760000118799. |
| HOVERGENi | HBG000490. |
| InParanoidi | P00533. |
| KOi | K04361. |
| OMAi | VCRKCHP. |
| OrthoDBi | EOG091G00NO. |
| PhylomeDBi | P00533. |
| TreeFami | TF106002. |
Family and domain databases
| Gene3Di | 3.80.20.20. 4 hits. |
| InterProi | View protein in InterPro IPR006211. Furin-like_Cys-rich_dom. IPR006212. Furin_repeat. IPR032778. GF_recep_IV. IPR009030. Growth_fac_rcpt_. IPR011009. Kinase-like_dom. IPR032675. L_dom-like. IPR000719. Prot_kinase_dom. IPR017441. Protein_kinase_ATP_BS. IPR000494. Rcpt_L-dom. IPR001245. Ser-Thr/Tyr_kinase_cat_dom. IPR008266. Tyr_kinase_AS. IPR020635. Tyr_kinase_cat_dom. IPR016245. Tyr_kinase_EGF/ERB/XmrK_rcpt. |
| Pfami | View protein in Pfam PF00757. Furin-like. 1 hit. PF14843. GF_recep_IV. 1 hit. PF07714. Pkinase_Tyr. 1 hit. PF01030. Recep_L_domain. 2 hits. |
| PIRSFi | PIRSF000619. TyrPK_EGF-R. 2 hits. |
| PRINTSi | PR00109. TYRKINASE. |
| SMARTi | View protein in SMART SM00261. FU. 3 hits. SM00219. TyrKc. 1 hit. |
| SUPFAMi | SSF52058. SSF52058. 2 hits. SSF56112. SSF56112. 1 hit. SSF57184. SSF57184. 2 hits. |
| PROSITEi | View protein in PROSITE PS00107. PROTEIN_KINASE_ATP. 1 hit. PS50011. PROTEIN_KINASE_DOM. 1 hit. PS00109. PROTEIN_KINASE_TYR. 1 hit. |
Sequences (4)i
Sequence statusi: Complete.
Sequence processingi: The displayed sequence is further processed into a mature form.
This entry describes 4 isoformsi produced by alternative splicing. AlignAdd to basket
Isoform 1 (identifier: P00533-1) [UniParc]FASTAAdd to basket
Also known as: p170
This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.
10 20 30 40 50
MRPSGTAGAA LLALLAALCP ASRALEEKKV CQGTSNKLTQ LGTFEDHFLS
60 70 80 90 100
LQRMFNNCEV VLGNLEITYV QRNYDLSFLK TIQEVAGYVL IALNTVERIP
110 120 130 140 150
LENLQIIRGN MYYENSYALA VLSNYDANKT GLKELPMRNL QEILHGAVRF
160 170 180 190 200
SNNPALCNVE SIQWRDIVSS DFLSNMSMDF QNHLGSCQKC DPSCPNGSCW
210 220 230 240 250
GAGEENCQKL TKIICAQQCS GRCRGKSPSD CCHNQCAAGC TGPRESDCLV
260 270 280 290 300
CRKFRDEATC KDTCPPLMLY NPTTYQMDVN PEGKYSFGAT CVKKCPRNYV
310 320 330 340 350
VTDHGSCVRA CGADSYEMEE DGVRKCKKCE GPCRKVCNGI GIGEFKDSLS
360 370 380 390 400
INATNIKHFK NCTSISGDLH ILPVAFRGDS FTHTPPLDPQ ELDILKTVKE
410 420 430 440 450
ITGFLLIQAW PENRTDLHAF ENLEIIRGRT KQHGQFSLAV VSLNITSLGL
460 470 480 490 500
RSLKEISDGD VIISGNKNLC YANTINWKKL FGTSGQKTKI ISNRGENSCK
510 520 530 540 550
ATGQVCHALC SPEGCWGPEP RDCVSCRNVS RGRECVDKCN LLEGEPREFV
560 570 580 590 600
ENSECIQCHP ECLPQAMNIT CTGRGPDNCI QCAHYIDGPH CVKTCPAGVM
610 620 630 640 650
GENNTLVWKY ADAGHVCHLC HPNCTYGCTG PGLEGCPTNG PKIPSIATGM
660 670 680 690 700
VGALLLLLVV ALGIGLFMRR RHIVRKRTLR RLLQERELVE PLTPSGEAPN
710 720 730 740 750
QALLRILKET EFKKIKVLGS GAFGTVYKGL WIPEGEKVKI PVAIKELREA
760 770 780 790 800
TSPKANKEIL DEAYVMASVD NPHVCRLLGI CLTSTVQLIT QLMPFGCLLD
810 820 830 840 850
YVREHKDNIG SQYLLNWCVQ IAKGMNYLED RRLVHRDLAA RNVLVKTPQH
860 870 880 890 900
VKITDFGLAK LLGAEEKEYH AEGGKVPIKW MALESILHRI YTHQSDVWSY
910 920 930 940 950
GVTVWELMTF GSKPYDGIPA SEISSILEKG ERLPQPPICT IDVYMIMVKC
960 970 980 990 1000
WMIDADSRPK FRELIIEFSK MARDPQRYLV IQGDERMHLP SPTDSNFYRA
1010 1020 1030 1040 1050
LMDEEDMDDV VDADEYLIPQ QGFFSSPSTS RTPLLSSLSA TSNNSTVACI
1060 1070 1080 1090 1100
DRNGLQSCPI KEDSFLQRYS SDPTGALTED SIDDTFLPVP EYINQSVPKR
1110 1120 1130 1140 1150
PAGSVQNPVY HNQPLNPAPS RDPHYQDPHS TAVGNPEYLN TVQPTCVNST
1160 1170 1180 1190 1200
FDSPAHWAQK GSHQISLDNP DYQQDFFPKE AKPNGIFKGS TAENAEYLRV
1210
APQSSEFIGA
Experimental Info
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Sequence conflicti | 540 | N → K in CAA25240 (PubMed:6328312).Curated | 1 |
Natural variant
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Natural variantiVAR_066493 | 30 – 297 | Missing Variant EGFR vIII; found in a lung cancer sample; somatic mutation; induces lung cancer when exogenously expressed. 1 PublicationAdd BLAST | 268 | |
| Natural variantiVAR_019293 | 98 | R → Q1 PublicationCorresponds to variant dbSNP:rs17289589Ensembl. | 1 | |
| Natural variantiVAR_019294 | 266 | P → R1 PublicationCorresponds to variant dbSNP:rs17336639Ensembl. | 1 | |
| Natural variantiVAR_072435 | 428 | G → D in NISBD2; loss of function; the mutant does not localize to the cell membrane; has diffuse cytoplasmic localization. 1 PublicationCorresponds to variant dbSNP:rs606231253Ensembl. | 1 | |
| Natural variantiVAR_019295 | 521 | R → K2 PublicationsCorresponds to variant dbSNP:rs2227983Ensembl. | 1 | |
| Natural variantiVAR_019296 | 674 | V → I1 PublicationCorresponds to variant dbSNP:rs17337079Ensembl. | 1 | |
| Natural variantiVAR_026084 | 709 | E → A Found in a lung cancer sample; more sensitive to gefitinib than wild-type. 3 PublicationsCorresponds to variant dbSNP:rs397517085Ensembl. | 1 | |
| Natural variantiVAR_069498 | 709 | E → G Found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type. 2 PublicationsCorresponds to variant dbSNP:rs397517085Ensembl. | 1 | |
| Natural variantiVAR_026085 | 709 | E → K Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs727504256Ensembl. | 1 | |
| Natural variantiVAR_026086 | 719 | G → A Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs121913428Ensembl. | 1 | |
| Natural variantiVAR_026087 | 719 | G → C Found in a lung cancer sample. 2 PublicationsCorresponds to variant dbSNP:rs28929495Ensembl. | 1 | |
| Natural variantiVAR_026088 | 719 | G → D Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs121913428Ensembl. | 1 | |
| Natural variantiVAR_019297 | 719 | G → S Found in a lung cancer sample; somatic mutation; strongly increased kinase activity; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type. 5 PublicationsCorresponds to variant dbSNP:rs28929495Ensembl. | 1 | |
| Natural variantiVAR_026089 | 724 | G → S Found in a lung cancer sample. 1 Publication | 1 | |
| Natural variantiVAR_026090 | 734 | E → K Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs121913420Ensembl. | 1 | |
| Natural variantiVAR_069499 | 746 – 752 | ELREATS → D Found in a lung cancer sample. 1 Publication | 7 | |
| Natural variantiVAR_069500 | 746 – 751 | ELREAT → A Found in a lung cancer sample. 1 Publication | 6 | |
| Natural variantiVAR_026092 | 746 – 750 | Missing Found in a lung cancer sample. 1 Publication | 5 | |
| Natural variantiVAR_026091 | 746 | Missing Found in a lung cancer sample. 1 Publication | 1 | |
| Natural variantiVAR_069501 | 747 – 751 | Missing Found in a lung cancer sample. 1 Publication | 5 | |
| Natural variantiVAR_026094 | 747 – 749 | Missing Found in a lung cancer sample. 1 Publication | 3 | |
| Natural variantiVAR_026093 | 747 | L → F Found in a lung cancer sample. 1 Publication | 1 | |
| Natural variantiVAR_026095 | 748 | R → P Found in a lung cancer sample. 1 Publication | 1 | |
| Natural variantiVAR_026096 | 752 – 759 | Missing Found in a lung cancer sample. 1 Publication | 8 | |
| Natural variantiVAR_069502 | 768 | S → I Found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type. 2 PublicationsCorresponds to variant dbSNP:rs121913465Ensembl. | 1 | |
| Natural variantiVAR_069503 | 769 | V → M Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs147149347Ensembl. | 1 | |
| Natural variantiVAR_026097 | 787 | Q → R Found in a lung cancer sample. 1 Publication | 1 | |
| Natural variantiVAR_026098 | 790 | T → M Found in a lung cancer sample; increased kinase activity. 2 PublicationsCorresponds to variant dbSNP:rs121434569Ensembl. | 1 | |
| Natural variantiVAR_026099 | 833 | L → V Found in a lung cancer sample; more sensitive to gefitinib than wild-type. 3 PublicationsCorresponds to variant dbSNP:rs397517126Ensembl. | 1 | |
| Natural variantiVAR_026100 | 834 | V → L Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs397517127Ensembl. | 1 | |
| Natural variantiVAR_069504 | 835 | H → L Found in a lung cancer sample; more sensitive to gefitinib than wild-type. 2 PublicationsCorresponds to variant dbSNP:rs397517128Ensembl. | 1 | |
| Natural variantiVAR_069505 | 838 | L → V Found in a lung cancer sample; more sensitive to gefitinib than wild-type. 2 PublicationsCorresponds to variant dbSNP:rs864621996Ensembl. | 1 | |
| Natural variantiVAR_026101 | 858 | L → M Found in a lung cancer sample. 1 PublicationCorresponds to variant dbSNP:rs121913443Ensembl. | 1 | |
| Natural variantiVAR_019298 | 858 | L → R Found in a lung cancer sample; somatic mutation; constitutively activated enzyme with strongly increased kinase activity; more sensitive to gefitinib than wild-type. 5 PublicationsCorresponds to variant dbSNP:rs121434568Ensembl. | 1 | |
| Natural variantiVAR_026102 | 861 | L → Q Found in a lung cancer sample; constitutively activated kinase with higher levels of basal autophosphorylation; more sensitive to gefitinib than wild-type. 3 PublicationsCorresponds to variant dbSNP:rs121913444Ensembl. | 1 | |
| Natural variantiVAR_026103 | 873 | G → E Found in a lung cancer sample. 1 Publication | 1 | |
| Natural variantiVAR_019299 | 962 | R → G1 PublicationCorresponds to variant dbSNP:rs17337451Ensembl. | 1 | |
| Natural variantiVAR_019300 | 988 | H → P1 PublicationCorresponds to variant dbSNP:rs17290699Ensembl. | 1 | |
| Natural variantiVAR_042095 | 1034 | L → R1 PublicationCorresponds to variant dbSNP:rs34352568Ensembl. | 1 | |
| Natural variantiVAR_042096 | 1210 | A → V1 PublicationCorresponds to variant dbSNP:rs35918369Ensembl. | 1 |
Alternative sequence
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| Alternative sequenceiVSP_002887 | 404 – 405 | FL → LS in isoform 2. 4 Publications | 2 | |
| Alternative sequenceiVSP_002888 | 406 – 1210 | Missing in isoform 2. 4 PublicationsAdd BLAST | 805 | |
| Alternative sequenceiVSP_002889 | 628 – 705 | CTGPG…QALLR → PGNESLKAMLFCLFKLSSCN QSNDGSVSHQSGSPAAQESC LGWIPSLLPSEFQLGWGGCS HLHAWPSASVIITASSCH in isoform 3. 1 PublicationAdd BLAST | 78 | |
| Alternative sequenceiVSP_002891 | 628 | C → S in isoform 4. 1 Publication | 1 | |
| Alternative sequenceiVSP_002892 | 629 – 1210 | Missing in isoform 4. 1 PublicationAdd BLAST | 582 | |
| Alternative sequenceiVSP_002890 | 706 – 1210 | Missing in isoform 3. 1 PublicationAdd BLAST | 505 |
Sequence databases
| Select the link destinations: EMBLi GenBanki DDBJi Links Updated | X00588 mRNA. Translation: CAA25240.1. U95089 mRNA. Translation: AAB53063.1. U48722 mRNA. Translation: AAC50802.1. U48723 Genomic DNA. Translation: AAC50804.1. U48724 Genomic DNA. Translation: AAC50796.1. U48725 Genomic DNA. Translation: AAC50797.1. U48726 Genomic DNA. Translation: AAC50798.1. U48727 Genomic DNA. Translation: AAC50799.1. U48728 Genomic DNA. Translation: AAC50800.1. U48729 Genomic DNA. Translation: AAC50801.1. AF288738 Genomic DNA. Translation: AAG35786.1. AF288738 Genomic DNA. Translation: AAG35787.1. AF288738 Genomic DNA. Translation: AAG35788.1. AF288738 Genomic DNA. Translation: AAG35789.1. AF288738 Genomic DNA. Translation: AAG35790.1. AY698024 mRNA. Translation: AAT97979.1. AY588246 Genomic DNA. Translation: AAS83109.1. AF277897 mRNA. Translation: AAK01080.1. AF125253 mRNA. Translation: AAG43240.1. AF125539, AF125538 Genomic DNA. Translation: AAG43243.1. X06370 Genomic DNA. Translation: CAA29668.1. X00663 mRNA. Translation: CAA25282.1. M38425 Genomic DNA. Translation: AAA63171.1. M11234 Genomic DNA. Translation: AAA52370.1. |
| CCDSi | CCDS47587.1. [P00533-2] CCDS5514.1. [P00533-1] CCDS5515.1. [P00533-3] CCDS5516.1. [P00533-4] |
| PIRi | A00641. GQHUE. |
| RefSeqi | NP_005219.2. NM_005228.4. [P00533-1] NP_958439.1. NM_201282.1. [P00533-4] NP_958440.1. NM_201283.1. [P00533-2] NP_958441.1. NM_201284.1. [P00533-3] |
| UniGenei | Hs.488293. Hs.605083. Hs.731652. |
Genome annotation databases
| Ensembli | ENST00000275493; ENSP00000275493; ENSG00000146648. [P00533-1] ENST00000342916; ENSP00000342376; ENSG00000146648. [P00533-4] ENST00000344576; ENSP00000345973; ENSG00000146648. [P00533-3] ENST00000420316; ENSP00000413843; ENSG00000146648. [P00533-2] |
| GeneIDi | 1956. |
| KEGGi | hsa:1956. |
| UCSCi | uc003tqh.4. human. [P00533-1] |
Keywords - Coding sequence diversityi
Alternative splicing, PolymorphismSimilar proteinsi
Links to similar proteins from the UniProt Reference Clusters (UniRef) at 100%, 90% and 50% sequence identity:| 100% | UniRef100 combines identical sequences and sub-fragments with 11 or more residues from any organism into one UniRef entry. |
| 90% | UniRef90 is built by clustering UniRef100 sequences that have at least 90% sequence identity to, and 80% overlap with, the longest sequence (a.k.a seed sequence). |
| 50% | UniRef50 is built by clustering UniRef90 seed sequences that have at least 50% sequence identity to, and 80% overlap with, the longest sequence in the cluster. |
Entry informationi
| Entry namei | EGFR_HUMAN | |
| Accessioni | P00533Primary (citable) accession number: P00533 Secondary accession number(s): O00688 Q9UMG5 | |
| Entry historyi | Integrated into UniProtKB/Swiss-Prot: | July 21, 1986 |
| Last sequence update: | November 1, 1997 | |
| Last modified: | July 5, 2017 | |
| This is version 242 of the entry and version 2 of the sequence. See complete history. | ||
| Entry statusi | Reviewed (UniProtKB/Swiss-Prot) | |
| Annotation program | Chordata Protein Annotation Program | |
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | |
Miscellaneousi
Keywords - Technical termi
3D-structure, Complete proteome, Direct protein sequencing, Reference proteomeDocuments
- Human chromosome 7
Human chromosome 7: entries, gene names and cross-references to MIM - Human entries with polymorphisms or disease mutations
List of human entries with polymorphisms or disease mutations - Human polymorphisms and disease mutations
Index of human polymorphisms and disease mutations - MIM cross-references
Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot - PDB cross-references
Index of Protein Data Bank (PDB) cross-references - Human and mouse protein kinases
Human and mouse protein kinases: classification and index - SIMILARITY comments
Index of protein domains and families - UniProtKB entry view manual
User manual for the UniProtKB entry view
